FDA Accepts for Priority Review Merck’s Supplemental New Drug Application for WELIREG in Certain Previously Treated Patients With Advanced RCC
Acceptance based on results from the Phase 3 LITESPARK-005 trial, which showed a statistically significant and clinically meaningful…